Coronavirus Update: Superior Tolerability Was Behind Pfizer/BioNTech’s Vaccine Switch
Far Fewer Suffered Fever Symptoms
Pfizer and BioNTech made a last-minute switch to new lead candidate ahead of a pivotal Phase II/III trial, in which 11,000 volunteers have now already been dosed worldwide.
You may also be interested in...
The UK backs the world's first COVID-19 human challenge studies to accelerate research – though the first results will not be ready until mid-2021.
New chief business officer named at Ovoca Bio, and a new chairman at Opthea Ltd.
Plus Sanofi and Translate Bio release preclinical data from their COVID-19 vaccine candidate, another entrant to the now crowded mRNA vaccine field.